A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.

Exclusion Criteria

• •1. The presence of overt leptomeningeal or active central nervous system (CNS) metastases, or CNS metastases that require local CNS-directed therapy or increasing doses of corticosteroids within the prior 2 weeks.
• •2. Impaired cardiac function or clinically significant cardiac disease.
• •3. Patients with interstitial pneumonia or history of drug-induced interstitial pneumonia/pneumonitis.
• •4. For patients with lymphoma:
• •* Systemic antineoplastic therapy (including cytotoxic chemotherapy, alfa-interferon \[INF\], and toxin immunoconjugates) or any experimental therapy within 3 weeks or 5 half lives, whichever is shorter, before the first dose of study treatment.
• •* Therapy with tyrosine kinase inhibitor within 5 half-lives before the first dose of study treatment.
• •* Unconjugated monoclonal antibody therapies \< 6 weeks before the first dose of study treatment.
• •5. Patients receiving systemic chronic steroid therapy or any immunosuppressive therapy (\>20 mg/day prednisone or equivalent).